This study investigates the effect of enzalutamide on patient-reported fatigue in prostate cancer patients using data from four pivotal, placebo-controlled trials (ARCHES, PROSPER, PREVAIL, and AFFIRM). Fatigue was assessed using the FACT-P GP1 item. Results showed an initial increase in fatigue in both enzalutamide and placebo groups within the first 13-17 weeks, with subsequent stabilization or improvement. Worsening of fatigue was more common with enzalutamide plus ADT in three of the four trials, except AFFIRM, which included a more symptomatic population. The findings highlight the need for clinical management of fatigue, especially early in treatment.
Publisher
Prostate Cancer and Prostatic Diseases
Published On
Sep 13, 2021
Authors
Bertrand F. Tombal, Stephen J. Freedland, Andrew J. Armstrong, Tomasz M. Beer, Arnulf Stenzl, Cora N. Sternberg, Maha Hussain, Arijit Ganguly, Krishnan Ramaswamy, Hemant Bhadauria, Cristina Ivanescu, James Turnbull, Stefan Holmström, Fred Saad
Tags
enzalutamide
fatigue
prostate cancer
clinical management
pivotal trials
Related Publications
Explore these studies to deepen your understanding of the subject.
